Micro-axial flow pump vs veno-arterial extracorporeal membrane oxygenation for high-risk percutaneous coronary interventions: a randomized trial.

Summary

In patients undergoing non-emergent high-risk PCI with LVEF ≤35%, 30-day major adverse events occurred in 7.34% with the SynFlow 3.0 micro-axial pump and 11.5% with VA-ECMO. The pump met the prespecified non-inferiority criterion and was associated with shorter hospitalization, fewer device-related adverse events, and less anemia.

Key Findings

• Thirty-day major adverse events occurred in 7.34% with SynFlow 3.0 versus 11.5% with VA-ECMO.
• The micro-axial flow pump was non-inferior to VA-ECMO for the primary 30-day endpoint.
• SynFlow 3.0 was associated with shorter hospital stay, fewer device-related adverse events, and less anemia.

Clinical Implications

For selected patients undergoing high-risk PCI with severely reduced LVEF, a micro-axial flow pump may be an alternative to VA-ECMO when temporary prophylactic support is required. Device selection should remain individualized according to hemodynamics, anatomy, institutional expertise, and bleeding or vascular risk.

Limitations

• The trial was open-label, which may introduce performance and ascertainment bias.
• The sample size was modest and the study was designed for non-inferiority rather than superiority.
• Results may not generalize to emergent PCI, profound cardiogenic shock, or centers without extensive mechanical-support expertise.

Future Directions

Larger pragmatic trials should evaluate mortality, cost-effectiveness, quality of life, and patient subgroups defined by shock severity, coronary anatomy, and ventricular function. Comparative studies of other micro-axial pumps and standardized escalation algorithms are also needed.